Compare IONQ Inc (IONQ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Novo Nordisk A/S — how do they compare? IONQ Inc trades at $35.61 (market cap $12.78B), while Novo Nordisk A/S trades at $49.63 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 17.3× IONQ Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.
| IONQ | NVO | |
|---|---|---|
Market Cap | $12.78B | $220.53B |
Sector | Technology | Health |
52-Week High | $82.09 | $71.70 |
52-Week Low | $26.59 | $35.29 |
Enterprise Value | $10.78B | $239.49B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $34.24, down 1.55% with a bearish technical signal despite bullish oscillators. The company shows strong revenue growth projections from $130M in 2025 to $187M in 2026, but remains unprofitable with a net loss of $510M in 2025. Analyst consensus is split with a $73.75 price target representing 115% upside potential. Recent news highlights IonQ's leadership in quantum computing platform development and government validation.
The stock offers significant upside potential based on analyst targets but faces execution risks in achieving profitability. High valuation multiples (P/E 89.18, P/S 58.73) reflect growth expectations, while negative cash flow from operations and competitive threats in quantum computing present substantial risks for investors.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
